Source 1primary paper2026MED
Toolkit/CAR-NK cells
CAR-NK cells
Also known as: CAR natural killer cells, chimeric antigen receptor (CAR)-NK cells, Chimeric antigen receptor-modified natural killer cells, chimeric antigen receptor natural killer cells
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising "off-the-shelf" alternative to CAR-T cells.
Usefulness & Problems
Why this is useful
CAR-NK cells are presented as an alternative CAR-engineered immune-cell platform for cancer treatment. The abstract highlights their HLA-independent cytotoxicity.; off-the-shelf CAR-based cancer immunotherapy; CAR-NK cells are engineered natural killer cells used as an off-the-shelf cellular immunotherapy platform. The abstract frames them as a safer alternative to CAR-T cells with inherent multi-antigen targeting capabilities.; off-the-shelf cellular immunotherapy; antitumor responses against hematological and solid malignancies; CAR-NK cells are an engineered NK-cell therapy presented as a next-generation immunotherapeutic approach after CAR-T cells. The abstract frames them as an off-the-shelf cell therapy platform with mitigated off-tumor toxicity.; off-the-shelf cancer immunotherapy; cell therapy with reduced off-tumor toxicity relative to CAR-T as described in the abstract; CAR-NK cells are engineered natural killer cells used as a cancer immunotherapy platform. The abstract presents them as an alternative to CAR-T therapies.; cancer immunotherapy; allogeneic cell therapy design; CAR-NK cells are engineered natural killer cells used as a cancer immunotherapy platform. The abstract specifically links them to safety and therapeutic activity in early-phase trials for lymphoid malignancies.; treatment of relapsed and refractory cancers; engineered NK-cell therapy for lymphoid malignancies; CAR-NK cells are identified as an emerging CAR-based approach in autoimmune diseases. The abstract includes them among engineered immune-cell strategies for targeted intervention.; autoimmune disease treatment
Source:
CAR-NK cells are presented as an alternative CAR-engineered immune-cell platform for cancer treatment. The abstract highlights their HLA-independent cytotoxicity.
Source:
off-the-shelf CAR-based cancer immunotherapy
Source:
CAR-NK cells are engineered natural killer cells used as an off-the-shelf cellular immunotherapy platform. The abstract frames them as a safer alternative to CAR-T cells with inherent multi-antigen targeting capabilities.
Source:
off-the-shelf cellular immunotherapy
Source:
antitumor responses against hematological and solid malignancies
Source:
CAR-NK cells are an engineered NK-cell therapy presented as a next-generation immunotherapeutic approach after CAR-T cells. The abstract frames them as an off-the-shelf cell therapy platform with mitigated off-tumor toxicity.
Source:
off-the-shelf cancer immunotherapy
Source:
cell therapy with reduced off-tumor toxicity relative to CAR-T as described in the abstract
Source:
CAR-NK cells are engineered natural killer cells used as a cancer immunotherapy platform. The abstract presents them as an alternative to CAR-T therapies.
Source:
cancer immunotherapy
Source:
allogeneic cell therapy design
Source:
CAR-NK cells are engineered natural killer cells used as a cancer immunotherapy platform. The abstract specifically links them to safety and therapeutic activity in early-phase trials for lymphoid malignancies.
Source:
off-the-shelf cancer immunotherapy
Source:
treatment of relapsed and refractory cancers
Source:
engineered NK-cell therapy for lymphoid malignancies
Source:
CAR-NK cells are identified as an emerging CAR-based approach in autoimmune diseases. The abstract includes them among engineered immune-cell strategies for targeted intervention.
Source:
autoimmune disease treatment
Problem solved
They are being investigated to address limitations of conventional CAR-T therapy, including manufacturing complexity and toxicities. The source also frames them as promising off-the-shelf options.; addresses limitations of conventional CAR-T therapy including complex manufacturing and treatment-related toxicities; They aim to provide durable, potent, and safe antitumor responses in hematological and solid malignancies. The platform is positioned as a more accessible cellular immunotherapy option.; providing an alternative to CAR-T cells with a superior safety profile and inherent multi-antigen targeting capabilities; The platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.; provides an alternative to CAR-T therapy with inherent off-the-shelf compatibility; aims to maintain favorable safety profiles while addressing solid tumor challenges; They aim to provide antitumor cell therapy with reduced toxicity and better allogeneic and manufacturing properties than CAR-T approaches.; providing an alternative engineered immune-cell therapy platform to CAR-T therapies; It addresses the need for scalable, off-the-shelf cell therapies for relapsed and refractory cancers. The abstract presents CAR-NK cells as a promising allogeneic immunotherapy platform.; provides an engineered NK-cell platform for cancer therapy; They are part of the review's set of approaches intended to move beyond conventional immunosuppression.; targeted immune-cell-based intervention in autoimmune disease
Source:
They are being investigated to address limitations of conventional CAR-T therapy, including manufacturing complexity and toxicities. The source also frames them as promising off-the-shelf options.
Source:
addresses limitations of conventional CAR-T therapy including complex manufacturing and treatment-related toxicities
Source:
They aim to provide durable, potent, and safe antitumor responses in hematological and solid malignancies. The platform is positioned as a more accessible cellular immunotherapy option.
Source:
providing an alternative to CAR-T cells with a superior safety profile and inherent multi-antigen targeting capabilities
Source:
The platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.
Source:
provides an alternative to CAR-T therapy with inherent off-the-shelf compatibility
Source:
aims to maintain favorable safety profiles while addressing solid tumor challenges
Source:
They aim to provide antitumor cell therapy with reduced toxicity and better allogeneic and manufacturing properties than CAR-T approaches.
Source:
providing an alternative engineered immune-cell therapy platform to CAR-T therapies
Source:
It addresses the need for scalable, off-the-shelf cell therapies for relapsed and refractory cancers. The abstract presents CAR-NK cells as a promising allogeneic immunotherapy platform.
Source:
provides an engineered NK-cell platform for cancer therapy
Source:
They are part of the review's set of approaches intended to move beyond conventional immunosuppression.
Source:
targeted immune-cell-based intervention in autoimmune disease
Problem links
addresses limitations of conventional CAR-T therapy including complex manufacturing and treatment-related toxicities
LiteratureThey are being investigated to address limitations of conventional CAR-T therapy, including manufacturing complexity and toxicities. The source also frames them as promising off-the-shelf options.
Source:
They are being investigated to address limitations of conventional CAR-T therapy, including manufacturing complexity and toxicities. The source also frames them as promising off-the-shelf options.
aims to maintain favorable safety profiles while addressing solid tumor challenges
LiteratureThe platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.
Source:
The platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.
provides an alternative to CAR-T therapy with inherent off-the-shelf compatibility
LiteratureThe platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.
Source:
The platform aims to provide safer and more readily deployable adoptive cell therapy than CAR-T cells. The review specifically positions synthetic biology as a way to improve CAR-NK performance against solid tumor barriers.
provides an engineered NK-cell platform for cancer therapy
LiteratureIt addresses the need for scalable, off-the-shelf cell therapies for relapsed and refractory cancers. The abstract presents CAR-NK cells as a promising allogeneic immunotherapy platform.
Source:
It addresses the need for scalable, off-the-shelf cell therapies for relapsed and refractory cancers. The abstract presents CAR-NK cells as a promising allogeneic immunotherapy platform.
providing an alternative engineered immune-cell therapy platform to CAR-T therapies
LiteratureThey aim to provide antitumor cell therapy with reduced toxicity and better allogeneic and manufacturing properties than CAR-T approaches.
Source:
They aim to provide antitumor cell therapy with reduced toxicity and better allogeneic and manufacturing properties than CAR-T approaches.
providing an alternative to CAR-T cells with a superior safety profile and inherent multi-antigen targeting capabilities
LiteratureThey aim to provide durable, potent, and safe antitumor responses in hematological and solid malignancies. The platform is positioned as a more accessible cellular immunotherapy option.
Source:
They aim to provide durable, potent, and safe antitumor responses in hematological and solid malignancies. The platform is positioned as a more accessible cellular immunotherapy option.
targeted immune-cell-based intervention in autoimmune disease
LiteratureThey are part of the review's set of approaches intended to move beyond conventional immunosuppression.
Source:
They are part of the review's set of approaches intended to move beyond conventional immunosuppression.
Published Workflows
Objective: Enhance NK cell anti-tumor activity by engineering a PD1-synNotch receptor that drives target-dependent effector responses against PDL1-positive breast cancer cells.
Why it works: The workflow couples rational receptor design and expression testing with functional co-culture assays so that only NK cells bearing the engineered PD1-synNotch receptor are evaluated for target-dependent cytokine production and cytotoxicity against PDL1-positive tumor cells.
PDL1-triggered activation through a PD1-synNotch receptorconditional cytokine secretion upon target-cell engagementsequence-based receptor design using UniProt database sequences3D structure model generation for optimizationlentiviral transductionco-culture functional testing
Stages
- 1.Chimeric receptor design and optimization(library_design)
To create and optimize the chimeric PD1-synNotch receptor before introducing it into NK cells.
Selection: Use UniProt database sequences and 3D structure models to design and optimize the PD1-Syn receptor.
- 2.NK-cell engineering with PD1-Syn receptor(library_build)
To generate NK cells carrying the PD1-synNotch construct for downstream testing.
Selection: Introduce the PD1-Syn receptor into NK cells by lentiviral transduction.
- 3.Receptor surface expression assessment(functional_characterization)
To confirm that the engineered receptor is present on the NK cell surface before functional co-culture testing.
Selection: Assess expression of PD1-Syn receptors on NK cell surfaces.
- 4.Co-culture functional evaluation with PDL1-positive breast cancer cells(confirmatory_validation)
To test whether the engineered NK cells produce the intended target-dependent functional outputs against relevant tumor cells.
Selection: Evaluate cytotoxic activity and IL-12 and IFNγ production upon interaction with PDL1-positive breast cancer cells.
Steps
- 1.Design the PD1-Syn chimeric receptor from UniProt sequencesengineered construct
Create the PD1-synNotch receptor construct for NK-cell engineering.
The receptor must be designed before it can be optimized or introduced into cells.
- 2.Generate 3D structure models for receptor optimizationengineered construct
Optimize the chimeric receptor design before cell engineering.
3D structure modeling is described after initial design and before lentiviral introduction into NK cells, indicating an optimization step prior to build-and-test.
- 3.Introduce the PD1-Syn receptor into NK cells by lentiviral transductionengineered construct
Generate engineered NK cells expressing the PD1-synNotch receptor.
Cell engineering follows receptor design and optimization so the construct can be tested in NK cells.
- 4.Assess PD1-Syn receptor surface expression on NK cellsengineered construct
Confirm that the engineered receptor is expressed on the NK-cell surface.
Expression is checked before functional co-culture testing so downstream activity can be interpreted in the context of successful receptor installation.
- 5.Co-culture engineered NK cells with PDL1-positive breast cancer cellsengineered construct
Trigger the engineered receptor with relevant target cells and evaluate functional responses.
Co-culture is performed after receptor expression assessment to test whether receptor-positive NK cells respond to target-cell engagement.
- 6.Measure cytotoxicity and IL-12 and IFNγ production after target-cell interactionengineered construct
Determine whether the engineered NK cells show the intended target-dependent antitumor outputs.
Functional readouts are measured after co-culture because they depend on interaction with the target cells.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
context-dependent transgene regulationDegradationhla-independent cytotoxicitymulti-antigen targetingtargeted dna insertionTranslation ControlTechniques
Computational DesignTarget processes
degradationeditingmanufacturingsignalingtranslationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
requires precision engineering approaches to improve persistence, trafficking, and tumor eradication; requires synthetic biology strategies to enhance physiological characteristics; must function in immunosuppressive tumor microenvironments; The platform requires NK cells and chimeric antigen receptor engineering, and the abstract further indicates that precision gene editing and synthetic biology approaches are being used to improve performance. Expansion to solid tumors also depends on engineering for persistence and tumor-microenvironment resistance.; requires NK-cell engineering; current expansion to solid tumors requires additional engineering for effector function, persistence, and resistance to immunosuppressive tumor microenvironment; antigen selection is critical; co-stimulatory domain design is important; safety control mechanisms are important
The abstract states that these therapies still face several challenges in clinical application.; still face several challenges in clinical application; The abstract states that CAR-NK clinical potential remains constrained by current engineering limitations, especially the "CRISPR ceiling" associated with DSB-based CRISPR-Cas9.; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; The abstract states that CAR-NK therapy is still limited by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments.; poor in vivo persistence; functional exhaustion in immunosuppressive tumor microenvironments; clinical translation remains constrained; The abstract indicates that challenges remain in solid tumors, especially around persistence, effector function, and resistance to the immunosuppressive tumor microenvironment.; solid tumors remain challenging; The abstract does not provide direct efficacy evidence for autoimmune disease and notes general translational barriers.; clinical translation is challenged by antigen specificity; clinical translation is challenged by long-term persistence; clinical translation is challenged by manufacturing feasibility
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successHuman Clinicaltherapeutic use
Inferred from claim c2 during normalization. Early-phase clinical trials demonstrated remarkable safety and encouraging therapeutic efficacy of CAR-NK cells in heavily pretreated patients with lymphoid malignancies. Derived from claim c2.
Source:
Supporting Sources
Source 2primary paper2026MED
Source 3primary paper2025MED
Source 4primary paper2025MED
Source 5primary paper2025MED
Source 6primary paper2025MED
Ranked Claims
CRISPR-associated transposases enable programmable targeted insertion strategies that can accommodate larger cassettes.
CRISPR-associated transposases now enable programmable, targeted insertion strategies that can accommodate larger cassettes
CAR-NK cells and CAR-γδ T cells exhibit HLA-independent cytotoxicity and are promising off-the-shelf therapeutic options.
Notably, CAR-NK and CAR-γδ T cells exhibit HLA-independent cytotoxicity, making them promising 'off-the-shelf' therapeutic options.
CAR-NK cells are a promising off-the-shelf alternative to CAR-T cells with a superior safety profile and inherent multi-antigen targeting capabilities.
Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising "off-the-shelf" alternative to CAR-T cells, offering a superior safety profile and inherent multi-antigen targeting capabilities.
Next-generation precision engineering tools are proposed to enhance three efficacy pillars in CAR-NK cells: persistence, trafficking, and tumor eradication.
These advanced technologies enable the precise enhancement of three fundamental pillars of efficacy: Persistence through endogenous cytokine armoring and metabolic engineering; Trafficking via chemokine receptor matching and stromal barrier degradation; and Tumor Eradication using logic-gated targeting, immunomodulatory payloads, and bispecific engagers.
Synthetic and epigenetic circuits provide dynamic context-dependent transgene control that avoids constitutive promoter-driven tonic signaling.
synthetic/epigenetic circuits provide dynamic, context-dependent transgene control that avoids constitutive promoter-driven tonic signaling
CAR-NK clinical potential is constrained by practical limitations of DSB-based CRISPR-Cas9, including chromosomal rearrangements, p53-mediated fitness loss, inefficient safe large multicistronic knock-ins, and rigid promoter-driven transgene expression that can cause tonic signaling.
their clinical potential is constrained by the "CRISPR ceiling", a set of practical limitations of DSB-based CRISPR-Cas9 such as DNA double-strand break (DSB)-associated chromosomal rearrangements and p53-mediated fitness loss, low efficiency for safe, large, multicistronic knock-ins, and rigid promoter-driven transgene expression that can cause tonic signaling.
Conventional CAR-T therapy has complex manufacturing and severe treatment-related toxicities that limit broader clinical application.
The complex manufacturing process and severe treatmentrelated toxicities further limit its broader clinical application. To address these challenges, researchers are investigating alternative CAR-engineered immune cells
CAR-macrophages phagocytose tumor cells, present antigens, and remodel the immunosuppressive tumor microenvironment.
Meanwhile, CAR-M not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment.
DSB-free base and prime editors reduce or eliminate DSB-associated genotoxic stress compared with nuclease cutting.
next-generation, DSB-free base and prime editors reduce or eliminate the DSB-associated genotoxic stress observed with nuclease cutting
Alternative CAR-engineered immune-cell therapies still face several challenges in clinical application.
Despite their potential, these innovative therapies still face several challenges in clinical application.
Base editing, epigenetic reprogramming, targeted transposon systems, and synthetic biology circuits can be synergistically integrated to overcome critical clinical challenges in CAR-NK engineering.
We detail how base editing, epigenetic reprogramming, targeted transposon systems, and synthetic biology circuits can be synergistically integrated to overcome critical clinical challenges.
Early-phase clinical trials demonstrated remarkable safety and encouraging therapeutic efficacy of CAR-NK cells in heavily pretreated patients with lymphoid malignancies.
CAR-NK cells are presented as a promising alternative to CAR-T therapies with reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Chimeric antigen receptor-modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing.
CAR-NK cell therapy is presented as a next-generation immunotherapeutic approach after CAR-T therapy with inherent off-the-shelf compatibility and mitigated off-tumor toxicity.
Chimeric antigen receptor natural Killer (CAR-NK) cells therapy represents a next-generation immunotherapeutic approach following CAR-T cells therapy, offering inherent "off-the-shelf" compatibility and mitigated off-tumor toxicity.
High-throughput discovery platforms have identified actionable gene targets for NK-cell reprogramming, supporting the design of multi-engineered CAR-NK cells for solid tumors.
Precision gene editing is being leveraged to enhance NK-cell effector function, persistence, and resistance to the immunosuppressive tumor microenvironment as therapies expand to solid tumors.
Synthetic biology is being used to enhance the physiological characteristics of CAR-NK cells and to support development of next-generation CAR-NK therapies for solid tumor challenges while maintaining favorable safety profiles.
This review examines recent advancements in synthetic biology aimed at enhancing the physiological characteristics of CAR-NK cells. By delineating the synergy between NK cells and synthetic biology toolkits, this work provides a roadmap for developing next-generation CAR-NK therapies capable of addressing solid tumor challenges while maintaining favorable safety profiles.
Clinical translation of CAR-NK cell therapy remains constrained by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments.
Despite these advantages, clinical translation remains constrained by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments (TME).
Dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing are highlighted as innovations that directly mitigate known mechanisms leading to therapeutic failure.
This "evasion-to-solution" framework highlights how innovations such as dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing directly mitigate known mechanisms that lead to therapeutic failure.
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
Linking tumor biology to engineering strategy provides a translational roadmap for rational design of more adaptable and resilient CAR-NK therapies.
By linking tumor biology to engineering strategy, this review offers a translational roadmap for the rational design of more adaptable and resilient CAR-NK therapies.
Approval Evidence
6 sources15 linked approval claimsfirst-pass slug car-nk-cells
Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising "off-the-shelf" alternative to CAR-T cells.
Source:
researchers are investigating alternative CAR-engineered immune cells, including CAR-NK cells
Source:
CAR-NK cells
Source:
Early-phase clinical trials have demonstrated remarkable safety and encouraging therapeutic efficacy of chimeric antigen receptor (CAR)-NK cells in heavily pretreated patients with lymphoid malignancies.
Source:
Chimeric antigen receptor-modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Source:
Chimeric antigen receptor natural Killer (CAR-NK) cells therapy represents a next-generation immunotherapeutic approach following CAR-T cells therapy, offering inherent "off-the-shelf" compatibility and mitigated off-tumor toxicity.
Source:
comparative advantagesupports
CAR-NK cells and CAR-γδ T cells exhibit HLA-independent cytotoxicity and are promising off-the-shelf therapeutic options.
Notably, CAR-NK and CAR-γδ T cells exhibit HLA-independent cytotoxicity, making them promising 'off-the-shelf' therapeutic options.
Source:
comparative advantagesupports
CAR-NK cells are a promising off-the-shelf alternative to CAR-T cells with a superior safety profile and inherent multi-antigen targeting capabilities.
Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising "off-the-shelf" alternative to CAR-T cells, offering a superior safety profile and inherent multi-antigen targeting capabilities.
Source:
design objectivesupports
Next-generation precision engineering tools are proposed to enhance three efficacy pillars in CAR-NK cells: persistence, trafficking, and tumor eradication.
These advanced technologies enable the precise enhancement of three fundamental pillars of efficacy: Persistence through endogenous cytokine armoring and metabolic engineering; Trafficking via chemokine receptor matching and stromal barrier degradation; and Tumor Eradication using logic-gated targeting, immunomodulatory payloads, and bispecific engagers.
Source:
limitationsupports
CAR-NK clinical potential is constrained by practical limitations of DSB-based CRISPR-Cas9, including chromosomal rearrangements, p53-mediated fitness loss, inefficient safe large multicistronic knock-ins, and rigid promoter-driven transgene expression that can cause tonic signaling.
their clinical potential is constrained by the "CRISPR ceiling", a set of practical limitations of DSB-based CRISPR-Cas9 such as DNA double-strand break (DSB)-associated chromosomal rearrangements and p53-mediated fitness loss, low efficiency for safe, large, multicistronic knock-ins, and rigid promoter-driven transgene expression that can cause tonic signaling.
Source:
limitationsupports
Conventional CAR-T therapy has complex manufacturing and severe treatment-related toxicities that limit broader clinical application.
The complex manufacturing process and severe treatmentrelated toxicities further limit its broader clinical application. To address these challenges, researchers are investigating alternative CAR-engineered immune cells
Source:
translational limitationsupports
Alternative CAR-engineered immune-cell therapies still face several challenges in clinical application.
Despite their potential, these innovative therapies still face several challenges in clinical application.
Source:
clinical translationsupports
Early-phase clinical trials demonstrated remarkable safety and encouraging therapeutic efficacy of CAR-NK cells in heavily pretreated patients with lymphoid malignancies.
Source:
comparative advantagesupports
CAR-NK cells are presented as a promising alternative to CAR-T therapies with reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Chimeric antigen receptor-modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Source:
comparative advantagesupports
CAR-NK cell therapy is presented as a next-generation immunotherapeutic approach after CAR-T therapy with inherent off-the-shelf compatibility and mitigated off-tumor toxicity.
Chimeric antigen receptor natural Killer (CAR-NK) cells therapy represents a next-generation immunotherapeutic approach following CAR-T cells therapy, offering inherent "off-the-shelf" compatibility and mitigated off-tumor toxicity.
Source:
discovery platform outputsupports
High-throughput discovery platforms have identified actionable gene targets for NK-cell reprogramming, supporting the design of multi-engineered CAR-NK cells for solid tumors.
Source:
engineering rationalesupports
Precision gene editing is being leveraged to enhance NK-cell effector function, persistence, and resistance to the immunosuppressive tumor microenvironment as therapies expand to solid tumors.
Source:
engineering strategysupports
Synthetic biology is being used to enhance the physiological characteristics of CAR-NK cells and to support development of next-generation CAR-NK therapies for solid tumor challenges while maintaining favorable safety profiles.
This review examines recent advancements in synthetic biology aimed at enhancing the physiological characteristics of CAR-NK cells. By delineating the synergy between NK cells and synthetic biology toolkits, this work provides a roadmap for developing next-generation CAR-NK therapies capable of addressing solid tumor challenges while maintaining favorable safety profiles.
Source:
limitationsupports
Clinical translation of CAR-NK cell therapy remains constrained by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments.
Despite these advantages, clinical translation remains constrained by poor in vivo persistence and functional exhaustion in immunosuppressive tumor microenvironments (TME).
Source:
modality scopesupports
The review covers CAR-T cells, CAR-Tregs, CAAR-T cells, CAR-NK cells, and CAR-macrophages as CAR-based approaches for autoimmune diseases.
Source:
translational positioningsupports
Linking tumor biology to engineering strategy provides a translational roadmap for rational design of more adaptable and resilient CAR-NK therapies.
By linking tumor biology to engineering strategy, this review offers a translational roadmap for the rational design of more adaptable and resilient CAR-NK therapies.
Source:
Comparisons
Source-stated alternatives
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Source-backed strengths
HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells; superior safety profile; inherent multi-antigen targeting capabilities; inherent off-the-shelf compatibility; mitigated off-tumor toxicity; reduced toxicity; allogeneic feasibility; flexible manufacturing; described as promising and scalable; described as off-the-shelf; early-phase trials showed remarkable safety and encouraging efficacy
Source:
HLA-independent cytotoxicity
Source:
promising off-the-shelf therapeutic option
Source:
promising off-the-shelf alternative to CAR-T cells
Source:
superior safety profile
Source:
inherent multi-antigen targeting capabilities
Source:
inherent off-the-shelf compatibility
Source:
mitigated off-tumor toxicity
Source:
reduced toxicity
Source:
allogeneic feasibility
Source:
flexible manufacturing
Source:
described as promising and scalable
Source:
described as off-the-shelf
Source:
early-phase trials showed remarkable safety and encouraging efficacy
Compared with CAAR-T cells
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-engineered macrophages
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-macrophages
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-MΦ
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-NK
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-T
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-T cells
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-T cell therapy
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-Tregs
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with CAR-T therapy
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with chimeric antigen receptor macrophage
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with chimeric antigen receptor macrophages
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with chimeric antigen receptor natural killer cells
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract does not name a direct alternative cell-therapy platform, but it contrasts current CAR-NK performance in lymphoid malignancies with ongoing efforts to adapt these therapies for solid tumors.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with chimeric antigen receptor T cells
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with Chimeric antigen receptor T-cell therapy
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.; The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T cells as the preceding immunotherapeutic approach.
Source:
The abstract explicitly contrasts CAR-NK cells with CAR-T therapies.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Compared with HER2-targeting CAR-M
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.; The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Shared frame: source-stated alternative in extracted literature
Strengths here: HLA-independent cytotoxicity; promising off-the-shelf therapeutic option; promising off-the-shelf alternative to CAR-T cells.
Relative tradeoffs: still face several challenges in clinical application; clinical potential is constrained by limitations of conventional DSB-based CRISPR-Cas9 engineering; poor in vivo persistence.
Source:
The review contrasts CAR-NK cells with conventional CAR-T therapy and alongside CAR-γδ T cells and CAR-macrophages.
Source:
The abstract contrasts CAR-NK cells with CAR-T cells, CAR-Tregs, CAAR-T cells, and CAR-macrophages.
Ranked Citations
- 1.
- 2.
- 3.
- 4.
- 5.
- 6.